Crescent Biopharma, INC. (CBIO) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Dec 4, 2025
• GlycoMimetics Reports Material Definitive Agreement & Asset Changes — Jun 18, 2025 Risk: medium
  GlycoMimetics, Inc. filed an 8-K on June 18, 2025, reporting several material events. These include entry into a material definitive agreement, completion of an
• GlycoMimetics Files 8-K: Shareholder Vote, Reg FD, Other Events — Jun 6, 2025 Risk: medium
  On June 5, 2025, GlycoMimetics, Inc. filed an 8-K report detailing several events. The company announced the submission of matters to a vote of its security hol
• GlycoMimetics Files 8-K Report — May 30, 2025 Risk: low
  On May 30, 2025, GlycoMimetics, Inc. filed an 8-K report. The filing indicates an 'Other Event' and is related to the company's ongoing operations and reporting
• GlycoMimetics Enters Material Definitive Agreement — Apr 29, 2025 Risk: medium
  On April 28, 2025, GlycoMimetics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
• GlycoMimetics Reports Agreement Termination & Director Changes — Feb 25, 2025 Risk: medium
  GlycoMimetics, Inc. reported on February 19, 2025, the termination of a material definitive agreement and changes in its board of directors and officer compensa
• GlycoMimetics Enters Material Definitive Agreement — Feb 14, 2025 Risk: medium
  GlycoMimetics, Inc. announced on February 14, 2025, that it has entered into a Material Definitive Agreement. The company also filed financial statements and ex
• GlycoMimetics Announces Executive and Director Changes — Jan 31, 2025 Risk: medium
  GlycoMimetics, Inc. announced on January 29, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certa
• 8-K Filing — Jan 13, 2025
• GlycoMimetics Faces Delisting Concerns — Dec 26, 2024 Risk: high
  GlycoMimetics, Inc. filed an 8-K on December 26, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of December
• Royalty Pharma to Acquire GlycoMimetics for $2.00/Share — Nov 7, 2024 Risk: medium
  GlycoMimetics, Inc. announced on November 7, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for $2.00 per share in c
• Royalty Pharma to Acquire GlycoMimetics for $203M — Oct 29, 2024 Risk: medium
  GlycoMimetics, Inc. announced on October 28, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for approximately $4.10
• Royalty Pharma to Acquire GlycoMimetics for $200M — Jul 30, 2024 Risk: medium
  GlycoMimetics, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for $200 million in cash. T
• GlycoMimetics Faces Delisting Concerns — Jun 26, 2024 Risk: high
  GlycoMimetics, Inc. filed an 8-K on June 26, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in Rockv
• GlycoMimetics Appoints New CMO, CFO, and Director — Jun 13, 2024 Risk: medium
  GlycoMimetics, Inc. announced on June 10, 2024, changes in its executive and director roles. Dr. Helen B. Foy was appointed as Chief Medical Officer, and Mr. Mi
• GlycoMimetics Files 8-K for Financial Statements and Exhibits — Jun 4, 2024 Risk: low
  On June 4, 2024, GlycoMimetics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures rel
• GlycoMimetics Files 8-K on Operations — May 6, 2024 Risk: low
  GlycoMimetics, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosu
• GlycoMimetics Files 8-K on Shareholder Votes and Financials — May 2, 2024 Risk: low
  GlycoMimetics, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not cont
• GlycoMimetics Files 8-K for Financials and Exhibits — Mar 1, 2024 Risk: low
  GlycoMimetics, Inc. filed an 8-K on March 1, 2024, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or
• GlycoMimetics Files 8-K on Material Agreement; Details Pending — Jan 2, 2024
  GlycoMimetics, Inc. filed an 8-K on January 2, 2024, to report an "Entry into a Material Definitive Agreement." While the filing confirms the event date and the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX